dotMD.com
✓ Translated by DotMD AI Clinical Council Source: JAMA network open • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #42714908
Plain-English Research Story • 8th-Grade Reading Level

New Insights on Desmodium styracifolium Total Flavone Capsules for Urolithiasis: A Phase 3: What a 606-Participant Study Found

A total of 606 participants were randomly assigned to receive Guang Jing (n = 458) or placebo (n = 148).

Original Paper Title: “Desmodium styracifolium Total Flavone Capsules for Urolithiasis: A Phase 3 Randomized Clinical Trial” (JAMA network open, 2026-09-01)

Elena Rostova (AI Quant) Rigor Score
93 / 100
Sample Size (Participants)
N = 606
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The Bottom-Line Finding: A total of 606 participants were randomly assigned to receive Guang Jing (n = 458) or placebo (n = 148).
  • Who Was Studied: Phase III Randomized Trial published in JAMA network open following 606 real-world participants.
  • Strength of the Evidence: Earned a 93/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.
The Full Story in Plain English

What the Study Found (In Plain English)

Why This Matters to You

To evaluate whether Guang Jing improves stone passage rates (SPRs) compared with placebo in adults with urolithiasis. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

How the Study Worked

To find out, researchers writing in JAMA network open conducted a phase iii randomized trial evaluating 606 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

What the Study Found in Plain English

A total of 606 participants were randomly assigned to receive Guang Jing (n = 458) or placebo (n = 148). Their mean (SD) age was 43.0 (12.0) years, 474 (78.2%) were male, and the mean (SD) stone size was 0.6 (0.1) cm. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

The Catch: What to Keep in Mind

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bottom Line: Your Next Step

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in JAMA network open (2026-09-01) • Study Design: Phase III Randomized Trial • Participants: N = 606 • Biostatistical Rigor Score: 93/100. Primary Takeaway: A total of 606 participants were randomly assigned to receive Guang Jing (n = 458) or placebo (n = 148).

Study Limitations & Caveats Before You Act

While this phase iii randomized trial scored 93/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Formal Peer-Reviewed Study Reference
“Desmodium styracifolium Total Flavone Capsules for Urolithiasis: A Phase 3 Randomized Clinical Trial”
Published in JAMA network open (2026-09-01) • PMID/ID: 42714908
Read Formal Study

Related DotMD Clinical Hubs & Price Ledgers

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42714908: New Insights on Desmodium styracifolium Total Flavone Capsules for Urolithiasis: A Phase 3: What a 606-Participant Study Found

3 of 3 Free Questions Remaining